Environmental (E)

Social (S)

Economic (E)

The Quick-Change Module can provide patients with personalized endoscopes, reducing medical waste and lowering carbon emissions.

Addressing the issue of healthcare workforce shortages

Promoting the upgrading of the domestic medical equipment industry and enhancing the competitiveness of domestically produced medical materials in the international market

Solutions

The Institute's technology integrates one-piece molding and omnidirectional swing in a micro soft-tube robot, AI-assisted cavitation identification and assisted guidance technology, and a lung biopsy system. It employs remote-controlled natural orifice surgery to overcome internal navigation challenges and directly reach lesions, addressing postoperative complications and providing an efficient medical robotic solution.

Technology Application

²  Integrated design of bending sections for multi-degree-of-freedom robotic flexible tubes with omnidirectional swing control (210°; minimum dimensions: OD 2.9 mm, ID 1.2 mm), enabling flexible operation without blind spots.

²  The brand-new natural orifice robotic surgery technology avoids bleeding and perforation caused by percutaneous biopsy. It can reach as deep as the segment No. 6 of the human lung, covering more than 90% of the lungs.

²  The internal automatic navigation system integrates preoperative planning pathway assistance and AI cavitation recognition guidance to achieve precise operational instructions.

Achievements

²  Linking the domestic related component supply chain to complete the feasibility verification of the tactile navigation endoscopic robot applied in endoscopic surgery, achieving non-invasive natural orifice interventional treatment.

²  ITRI has collaborated with the NTU Hospital Hsinchu Campus and the Animal Technology Laboratory, Agricultural Technology Research Institute, and the preclinical animal trials have been completed. Director Yang Shun-Mao of the NTU Hospital Hsinchu Campus operated the tactile navigation endoscopic robot, achieving remote medical device collaboration, providing clinical operation feedback, and optimizing treatment outcomes.

²  Winning the "2024 R&D 100 Awards" and the "21st National Innovation Award."

Environmental (E)

Social (S)

Economic (E)

Centering on precision therapy, reducing excessive medical waste, and enhancing the utilization rate of medical resources

The cost is approximately one-tenth of that of current cell therapy products, providing patients with affordable, safe, and effective cell therapies, significantly improving patient survival rates and quality of life

The technology utilizes innovative technologies to overcome traditional limitations, achieves the pharmaceutical formulation of cell therapy, and promotes the development of innovative industries. By leveraging cost advantages, it creates higher economic benefits and becomes the future economic driving force of the biotechnology industry

Solutions

The Key Functional Cell Identity (KFCI) is a precision and standardized cell screening platform established for allogeneic cell therapy. It can rapidly select high-quality cells and identify the optimal corresponding diseases, overcoming the traditional difficulties of time-consuming and labor-intensive efforts to find suitable donors, which delay the critical treatment window. Furthermore, it improves surgical success rates and accelerates the development of cell therapy products.

Technology Application

²  Characteristics of the "Key Functional Cell Identity" cell screening platform:

Smarter Identification: Utilizing precise single-molecule recognition technology, it is possible to filter out lower-quality cells and, in conjunction with 40 types of indications, determine the most suitable therapeutic use for each individual cell.

²  More Cost-Efficient: Through systematic recognition and screening, the cost estimate is only one-tenth that of the current cell therapy products.

²  Increased Flexibility: Capable of commercial mass production, one donor's cells can produce 100,000 to 500,000 doses of the preparation. In cases of critical patients, cells that are safe and effective can be immediately accessed, significantly improving patient survival rates and quality of life.

Achievements

²  In 2024, the technology was honored with the Silver Award of the Edison Awards. The selected cell products have passed two TFDA clinical trial applications and are applied in the treatment of acute myocardial infarction and diabetic foot ulcer.